OncoMatch/Clinical Trials/NCT06403735
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Is NCT06403735 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies QLC1101 for non-small cell lung cancer.
Treatment: QLC1101 — QLC1101 is a selective reversible inhibitor of KRAS G12D, with the dosage form of capsules and administration route of oral administration. In the first-in-humans (FIH) study, the sponsor will explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of QLC1101 in subjects with advanced solid tumors harboring a KRAS G12D mutation. The FIH study includes dose escalation, PK expansion, and efficacy expansion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Pancreatic Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS g12d mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: kras g12d inhibitor
Lab requirements
Blood counts
adequate organ function at screening
Kidney function
adequate organ function at screening
Liver function
adequate organ function at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06403735 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior kras g12d inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12d mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify